350 related articles for article (PubMed ID: 22624470)
1. [Increasing the immunogenicity of inactivated chitosan adjuvanted vaccine from A/California/7/09 (H1N1) strain and analyzing the antigenic specificity of this influenza virus strain].
Gendon IuZ; Markushin SG; Vasil'ev IuM; Akopova II; Krivtsov GG
Vopr Virusol; 2012; 57(1):28-33. PubMed ID: 22624470
[TBL] [Abstract][Full Text] [Related]
2. [Chitosan as an adjuvant for parenteral inactivated influenza vaccines].
Gendon IuZ; Markushin SG; Krivtsov GG; Akopova II
Vopr Virusol; 2008; 53(5):14-9. PubMed ID: 19069787
[TBL] [Abstract][Full Text] [Related]
3. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
[TBL] [Abstract][Full Text] [Related]
4. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
5. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
[TBL] [Abstract][Full Text] [Related]
7. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
8. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
[TBL] [Abstract][Full Text] [Related]
9. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
10. [COMPARATIVE IMMUNOGENICITY STUDIES OF ADJUVANTS FROM VARIOUS SOURCES AND WITH DIFFERENT MECHANISMS OF ACTION FOR INACTIVATED INFLUENZA VACCINES].
Chernikova MI; Kashirina OS; Vasiliev YM
Zh Mikrobiol Epidemiol Immunobiol; 2015; (6):63-71. PubMed ID: 26950991
[TBL] [Abstract][Full Text] [Related]
11. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
12. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
13. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
[TBL] [Abstract][Full Text] [Related]
14. [Immune protective effectiveness of seasonal influenza spilt vaccine against homologous and heterogonous subtypes of influenza virus in mice].
Huang BY; Wang XP; Wang WL; Hu W; Gao Q; Tan WJ; Ruan L
Bing Du Xue Bao; 2011 May; 27(3):265-73. PubMed ID: 21774253
[TBL] [Abstract][Full Text] [Related]
15. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
[TBL] [Abstract][Full Text] [Related]
16. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
[TBL] [Abstract][Full Text] [Related]
17. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
[TBL] [Abstract][Full Text] [Related]
18. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
19. Seasonal influenza vaccine provides priming for A/H1N1 immunization.
Del Giudice G; Stittelaar KJ; van Amerongen G; Simon J; Osterhaus AD; Stöhr K; Rappuoli R
Sci Transl Med; 2009 Dec; 1(12):12re1. PubMed ID: 20371459
[TBL] [Abstract][Full Text] [Related]
20. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
